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Abstract
Huntingtin Interacting Protein 14 (HIP14) is a palmitoyl acyl transferase (PAT) that was first identified due to altered
interaction with mutant huntingtin, the protein responsible for Huntington Disease (HD). HIP14 palmitoylates a specific set
of neuronal substrates critical at the synapse, and downregulation of HIP14 by siRNA in vitro results in increased cell death in
neurons. We previously reported that mice lacking murine Hip14 (Hip142/2) share features of HD. In the current study, we
have generated human HIP14 BAC transgenic mice and crossed them to the Hip142/2 model in order to confirm that the
defects seen in Hip142/2 mice are in fact due to loss of Hip14. In addition, we sought to determine whether human HIP14
can provide functional compensation for loss of murine Hip14. We demonstrate that despite a relative low level of
expression, as assessed via Western blot, BAC-derived human HIP14 compensates for deficits in neuropathology, behavior,
and PAT enzyme function seen in the Hip142/2 model. Our findings yield important insights into HIP14 function in vivo.
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Introduction
Protein palmitoylation involves the reversible addition of
palmitic acid to cysteine residues via a thioester bond, and plays
a key role in protein trafficking and neuronal function [1,2].
Twenty-three mammalian palmitoyl-acyl transferases (PATs), each
bearing a characteristic DHHC domain [3] and displaying distinct
substrate specificity [4] were identified as the enzymes responsible
for catalyzing protein S-palmitoylation. Palmitoylation plays
a critical role in neuronal function and health [5,6]. For example,
PAT dysfunction or loss has been associated with several human
diseases, including mental retardation (OMIM *300646, *300576)
[7,8], schizophrenia (OMIM *608784) [9–11], and Alzheimer’s
Disease (#104300) [12]. In contrast, far less is known about the
acyl protein thioesterases that are thought to catalyze palmitate
removal [13], but their importance in regulation of protein
palmitoylation has been highlighted by patients with mutations in
the thioesterase PPT1 (Entrez Gene ID 5538) that result in
neuronal ceroid lipofuscinosis [14].
Huntington Disease (HD, OMIM #143100) is an autosomal
dominant neurodegenerative disease that presents with cognitive,
motor, and psychiatric signs and symptoms [15]. Striatal volume
loss due to medium spiny neuron (MSN) degeneration is a key
feature of the disease [16]. HD results from an expansion of the
CAG repeat in the HD gene, resulting in a polyglutamine (poly-Q)
expansion in the N-terminus of the huntingtin (HTT) protein [17].
Huntingtin Interacting Protein 14 (HIP14, Entrez Gene ID
23390), also known as DHHC17, was first identified as part of
a yeast-two-hybrid screen for proteins that interact with HTT
(Entrez Gene ID 3064) [18]. Sequence similarity of HIP14 to
Akr1p (Entrez Gene ID 851857; one of the first reported PATs
and a protein required for endocytosis) together with the ability of
human HIP14 to rescue Akr1p trafficking defects, led to the formal
description of HIP14 as the first mammalian PAT soon after [19].
Many widely divergent proteins interact with HTT [20].
However, HIP14 was selected for further study because its
interaction with HTT is reduced in the presence of the mutation
responsible for HD [18], resulting in less robust palmitoylation of
HIP14 substrates [21] fulfilling genetic criteria for having
a potential relationship to the disease. The enrichment of HIP14
in the brain, its expression in the medium spiny neurons primarily
affected in HD, and its co-localization with HTT are all features
supportive of a role for HIP14 in the pathogenesis of HD [18].
HIP14 demonstrates PAT substrate specificity for many neuronal
proteins, including HTT as well as PSD-95 (Entrez Gene ID
1742), SNAP-25 (Entrez Gene ID 6616), and NR2B (Entrez Gene
ID 2904) [19]. More recently, the major site of palmitoylation of
HTT was identified as cysteine 214 and mutation of this site,
rendering HTT non-palmitoylatable, increases inclusion forma-
tion and neuronal toxicity. Similar results are obtained by treating
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the appearance of inclusions [22].
Evidence supporting a protective role for HIP14 and further
implicating HIP14 in the pathogenesis of HD was obtained
through generation and characterization of a mouse lacking
murine Hip14 (Hip142/2, Entrez Gene ID 320150) [23]. These
mice bear features similar to those seen in the YAC128 mouse
model of HD. The latter transgenic model is widely studied and
recapitulates many features of human HD, including loss of MSNs
and striatal volume with accompanying motor, cognitive, and
affective dysfunction [24–26]. However, these phenotypes appear
earlier in the Hip142/2 mouse and are of greater severity, in
addition to being non-progressive [23]. For example, the Hip142/
2 mouse displays a 17% loss in striatal volume by embryonic day
E17.5, as compared to 9 months in the YAC128 mouse [24]. In
addition, the Hip142/2 mice demonstrate deficits in motor
function and palmitoylation of HIP14 substrates, again both
features observed in the YAC128 model.
Due to the putative protective role for HIP14 in HD suggested
by features of HD observed in the Hip142/2 mice, we sought to
create a mouse that overexpresses HIP14 in order to obtain
a greater understanding of HIP14 biology in vivo. To help ensure
a pattern of HIP14 overexpression closely resembling that of
normal physiology, we selected a Bacterial Artificial Chromosome
(BAC) transgenic approach, which permits inclusion of endoge-
nous regulatory DNA surrounding the gene of interest [27,28].
Because our primary goal remains to understand HIP14 biology as
it pertains to human disease, we selected a human HIP14
transgene.
The advantages of using the human gene when generating
transgenic mice in relation to the study of human disease has been
demonstrated in mouse models where the human gene is used in
artificial chromosome systems of transgenesis [29,30]. These
studies have been highly successful in generating mice that
accurately recapitulate the key aspects of the disease phenotype
and likely the underlying molecular cause of disease in patients,
rendering these models suitable for future use in preclinical studies.
Ultimately, a mouse overexpressing human HIP14 may be crossed
to mouse models of HD, anticipating that HIP14 overexpression
might delay the onset of the features of HD, or reduce their
severity.
Because of the very high level of sequence conservation between
human and mouse HIP14 protein (98% identical), we predicted
that human HIP14 would be compatible with the murine cellular
and transcriptional machinery. Previous studies demonstrate that
many human proteins can fully [29,31] or partially [32–35] rescue
the murine null phenotype.
The objective of this study was to confirm that defects seen in
Hip142/2 mice are indeed the result of the absence of HIP14. In
addition, we sought to determine the levels of HIP14 sufficient to
rescue the phenotype in Hip142/2 mice and whether certain
endpoints are more sensitive to loss of murine Hip14. Finally, we
wanted to address whether human HIP14 can compensate for loss
of the murine protein.
In this study, we have generated a human HIP14 BAC
transgenic mouse and confirmed a functional rescue of the
neuropathological, behavioral, and enzymatic deficits observed in
the Hip142/2 mouse by the human HIP14 transgene. In this
humanized mouse model, we report that human HIP14
Table 1. Sequences of primers used in this study.
Primer name Description Application Primer sequence
1 HIP14h_Pr1 Upstream/promoter area 1 F PCR genotyping cccagaggtccaaacaacat
R gcttttccaaccaggcttc
2 HIP14h_Pr2 Upstream/promoter area 2 F PCR genotyping tatttccctgcttccaatgc
R ttccccacttcctgtctctg
3 HIP14h_Ex1 Exon 1 F PCR genotyping cgggaggagggatttaacac
R gagtccggggaagaaagg
4 HIP14h_Int1 Intron 1 F PCR genotyping gaaccgtgctgagtggattc
R acacctccacctctgtcctc
5 Ex_7 Exon 7 F PCR genotyping cacagtcattagccttcttctgg
R gggtcctcctatcaacaccat
6 STOP Stop codon (spans stop codon) F PCR genotyping tttggggtgctgtttttagc
R attttcaggcaccactcagc
7 39UTR 39 untranslated region F PCR genotyping aatgggcgtaaaacagcatc
R ccacagaataacacggtaagtagc
8 hHIP14 F2/R2 Exon 1 F qPCR ccccgggagggtgaaac
R agcccgcttcggtatcgta
9 hHIP14 F1/R1 Exon 1–2 (intron-spanning) F qRT-PCR taccgaagcgggctgtgt
R agttttccgtccaagaggttcac
10 mHIP14 rt2f_F1/R1 Exon 14–15 (intron spanning) F qRT-PCR tggttgtgtctcttactgggg
R catccacggggagcatgtg
11 mbact F1/R1 mouse actin (endogenous control) F qPCR & qRT-PCR acggccaggtcatcactattg
R caagaaggaaggctggaaaaga
doi:10.1371/journal.pone.0036315.t001
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Materials and Methods
All experiments were carried out in accordance with protocols
(Animal protocols A07-0106 and A07-0262) approved by the UBC
Committee on Animal Care and the Canadian Council on Animal
Care.
Generation of HIP14 BAC mice & animal breeding
strategy
A ,190 kb long human Bacterial Artificial Chromosome (BAC)
containing the entire HIP14 gene (RP11-463M12) was obtained
from the Children’s Hospital Oakland Research Institute
(CHORI) (Figure S1a).
BAC DNA was prepared according to a standard protocol
obtained from the Rockefeller University NINDS GENSAT BAC
Transgenic project (http://www.gensat.org/GensatProtocols.pdf),
microinjected into FVB/N fertilized embryos, and implanted in
pseudopregnant female mice. Seven human-specific primers
spanning the HIP14 gene and surrounding sequence were
designed in order to characterize founders carrying the entire
construct, and for subsequent routine PCR genotyping (Table 1).
Animal breeding strategy
BAC founders were identified using a standard genotyping
protocol. The highest-expressing line (HB4) was chosen for further
study, and BAC,Hip14+/26HIP14+/2 matings were set up to
obtain mice for use in the study, namely wildtype (WT) (Hip14+/
+), Hip142/2 (Hip142/2), and the humanized BAC mice
(BAC,Hip142/2).
Figure 1. HIP14 mRNA and protein expression in Hip142/2 and HIP14 BAC mice. Human HIP14 mRNA (a) is expressed in BAC mice
(p,0.0001) and no signal is detected in WT or Hip142/2 littermates (ANOVA p,0.0001, n=6). Murine Hip14 mRNA transcript (b) is significantly
reduced in Hip142/2 mice (p,0.0001) and is not altered in the presence of human HIP14 (ANOVA p,0.0001, n=6). Primers for mouse actin were
used as an endogenous control. HIP14 protein expression in striatum (c) and cortex (d) was assessed by western blot using an in-house HIP14
polyclonal antibody. Beta-tubulin was used as a loading control. Striatum and cortex both n=5. Post-hoc Tukey tests: ***p,0.0001.
doi:10.1371/journal.pone.0036315.g001
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reactions: One for the human HIP14 BAC (Table 1, primer pair
5), and one for mouse Hip14 as described previously [23].
Genotypes of mice were re-confirmed at time of sacrifice.
Transgene copy number assessment by quantitative PCR
A primer pair specific for human HIP14 exon 1 (Table 1, primer
pair 8) was designed using Primer Express 3.0 software (ABI).
Relative transgene copy number was assessed on the ABI 7500
Fast system using Power SYBR Green PCR Mastermix (Applied
Biosystems) and the relative quantitation settings. Signal was
normalized to mouse actin (Table 1, primer pair 11).
Isolation of RNA & quantitative RT-PCR
Total RNA was isolated using the Qiagen RNeasy Plus Mini kit
according to the kit instructions. Samples were subsequently
treated with DNase I (Invitrogen). cDNA was generated using the
SuperScriptH III First-Strand Synthesis System (Invitrogen). qRT-
PCR was performed on the ABI 7500 Fast Real Time PCR
System (Applied Biosystems).
Primers specific for human HIP14 mRNA (Table 1, primer pair
9) were used in Figure 1a. For Figure 1b, primers specific for
murine Hip14, annealing 39 to the gene-trap site in intron 5 were
used. Relative gene expression was normalized to mouse actin (as
above).
Preparation of protein lysate and Western Blots
1 month mouse cortex or striatum tissue was homogenized
using a Dounce homogenizer on ice in 1 volume of TEEN
(50 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM
NaCl) +1% SDS buffer. After initial lysis, 4 volumes of TEEN
+1% Triton X-100 was added. The sample was passed through
a 25 gauge needle 5 times and sonicated for 5 seconds on 20%
power, spun at 14,000 rpm at 4 degrees for 15 minutes, and the
supernatant transferred to a new tube. Protein concentration was
determined using the Bradford Assay (Biorad). The above buffers
were supplemented with the following reagents: 16 Complete
Protease Inhibitors (Roche), 1 mM sodium orthovanadate (Sigma),
800 mM PMSF (Sigma), 5 mM zVAD (Calbiochem). Equal
amounts of protein were loaded and run on 4–12% Bis-Tris
SDS-PAGE gels (Invitrogen). Immunoblots were obtained using
an in-house polyclonal rabbit HIP14 antibody (PEP1) described
previously [18]. Beta tubulin antibody T4026 was assessed as
a loading control (Sigma).
Stereology & Neuropathological Assessments
Mice aged 1 month received tail injections of heparin and were
terminally anesthetized by intraperitoneal injection of avertin,
followed by intracardiac perfusion with fresh cold 4% para-
formaldehyde in PBS, pH 7.0 for 10 minutes. Neuropathological
assessments were performed as previously described [24]. All
analysis was performed with the researcher blind to genotypes.
Quantification of DARRP-32, Enkephalin and Substance P
Immunohistochemistry staining
Immunohistochemistry was performed on 1 month old mice of
mixed gender.
Primary antibodies were: mouse anti-DARPP32, #C24-6a
(from Dr. P. Greengard and Dr. H. Hemming), rabbit anti-
enkephalin (Chemicon), rat anti-substance P (Accurate Chemical).
Sections were incubated with horseradish peroxidase (HRP)
conjugated secondary antibodies (Jackson ImmunoResearch Lab-
oratories) followed by DAB and 0.5% cresyl violet and visualized
using a Zeiss Axioplan 2 microscope. Staining was quantified using
MetaMorph (Universal Imaging Corporation). Relative levels of
staining were calculated as the sum of the integrated optical
density divided by the area selected, then multiplied by the
sampling interval (68) and section thickness (25 mm). The
individual values were normalized to wild type.
Behavioral analysis
Mice were acclimatized to the behavioral testing holding room
under reverse lighting (12–10 pm dark cycle) at least one week
prior to behavioral testing at 3 months. Group-housed mice of
both genders were assessed. Single-housed mice were removed
from the analysis, and the experimenter was blind to genotype.
Table 2. A table summarizing the genotyping results for the 11 founders.
Primer Primer 1 Primer 2 Primer 3 Primer 4 Primer 5 Primer 6 Primer 7
Region
Promoter
region 1
Promoter
region 2 Exon 1 Intron 1 Exon 7 STOP 39 UTR
Founder line
HB1 + ++++++
HB2 + ++++++
HB3 + ++++++
HB4 + ++++++
HB5 + ++++++
HB6 + ++++++
HB7 + ++++++
HB8 ++ 22222
HB9 + ++++++
HB10 ++ + 2222
HB11 + ++++++
A‘ ‘ +’’ sign indicates that a PCR product was detected. A ‘‘2’’ sign indicates that no PCR product was detected, suggesting that a truncated BAC construct was
integrated in these lines.
doi:10.1371/journal.pone.0036315.t002
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balance. Motor coordination and balance was assessed as
latency to fall on the accelerating rotarod apparatus (Ugo-Basile,
Norfolk, UK). Mice were trained for 3 days on a fixed-speed
rotarod at 3 months of age. On the fourth day, mice were tested
for latency to fall on an accelerating rotarod apparatus as
described [25]. Testing was repeated at 6 months of age (without
further training).
Med Associates spontaneous activity. Spontaneous activ-
ity was assessed using the Med Associates activity monitor system
(Med Associates Inc., St Albans, VT, USA) as described [23].
Mice were given transgel (Charles River) and acclimatized to the
room for at least 1 hour prior to testing, and testing did not
commence until 1 hour after the beginning of the dark lighting
cycle. The chamber was cleaned with ethanol and allowed to dry
between each animal. Each mouse was placed in the center of the
testing chamber. Spontaneous activity was recorded for 1 hour.
Palmitoylation assays
Protein palmitoylation was assessed using the Acyl-Biotin-
Exchange with Immunoprecipitation (ABE/IP) method [36] as
described previously [23]. For PSD-95, rabbit polyclonal antibody
used for IP was generously provided by the late Dr. Alaa El-
Husseini. PSD-95 mouse monoclonal antibody MAI-25629 was
used for western blot (Affinity Bioreagents, Golden, CO).
For SNAP-25, a mouse monoclonal antibody SMI-81 (Covance,
Emeryville, CA) was used for IP, and a rabbit polyclonal SNAP-25
antibody used for western blot (Synaptic Systems #111 002).
Palmitoylation (the Biotin-BMCC label) was detected using
a Streptavidin Alexa Fluor 680 conjugate antibody (Molecular
Probes #S-32358). All palmitoylation assessments were done on
whole brain of mice of combined gender aged 1–3 months. Each
sample was split in two and processed as technical replicates, in
order to reduce assay variability.
Body weight
Body weight of mice was recorded at 3 & 6 months of age prior
to behavioral testing.
Figure 2. HIP14 rescues the neuropathological deficits seen in the Hip142/2 mouse. Mice aged 1 month were perfused with 4% PFA and
sectioned using a cryostat, stained with anti-NeuN, mounted and volumes and neuronal counts were measured using Stereo investigator. a. Total
brain weight shows a trend to rescue in mice aged 1 month, although one-way ANOVA analysis is not significant (WT: 321.563.78, Hip142/2:
309.863.74, BAC: 319.265.32 g, ANOVA p=0.14). Pairwise t-tests reveal that Hip142/2 whole brain weight is significantly decreased compared to
WT (p=0.04) and that BAC do not differ from WT (p=0.7). b. Cerebellum weight is significantly decreased in Hip142/2 mice and is rescued to WT
levels in BAC mice at 1 month (WT: 51.4160.82, Hip142/2: 46.4560.83, BAC: 50.3461.38 g, ANOVA p=0.0038). Pairwise t-test analysis similarly
reveals that Hip142/2 cerebellum is significantly decreased compared to WT (p=0.0003) and that BAC do not differ from WT (p=0.5). c. Forebrain
weight shows a similar trend to rescue at 1 month of age (WT: 270.163.15, Hip142/2: 263.463.06, BAC: 268.964.27 g, ANOVA p=0.36). d. Striatal
volume is significantly rescued in BAC mice at 1 month of age (WT:10.460.3, Hip142/2: 8.860.4 mm
3, BAC: 10.360.2 mm
3; ANOVA p=0.002). e.
Striatal neuron count is likewise rescued by the human HIP14 BAC at 1 month of age (WT:2.060.1, Hip142/2: 1.760.08, BAC: 2.160.03 million cells;
ANOVA p=0.004). f. Finally, cortical volume loss observed in Hip142/2 mice is also rescued by human HIP14 at 1 month (WT:26.8660.52, Hip142/2:
23.6660.75, BAC: 26.2260.60 mm
3; ANOVA p=0.003). Similar observations are made at 3 months of age (data not shown). 1 month n=12, 12, and
11 for WT, Hip142/2, and BAC respectively. * p,0.05, **p,0.01, ***p,0.0001.
doi:10.1371/journal.pone.0036315.g002
Human HIP14 Rescues Loss of Murine HIP14 In Vivo
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36315Statistical Analysis
All statistical analyses were performed using the Graphpad
Prism software, version 5a. Parametric analysis of single timepoint
data was performed using one-way ANOVA, with post-hoc Tukey
test. Non-parametric analysis (for western blot and palmitoylation
assays) was done using the one-way ANOVA Kruskal-Wallis test
with post-hoc analysis using Dunn’s Multiple comparison test.
Behavioral data collected over multiple time points is assessed
using repeated measures ANOVA with Bonferroni post-hoc
analysis. Data are reported as mean 6 SEM.
Results
Generation of HIP14 BAC mice
A total of 494 FVB/N embyros were injected with a human
HIP14 BAC containing the entire HIP14 gene, 378 of which
survived and were implanted to pseudopregnant females. Forty-
five live-born pups were produced, of which 11 were positive for
the BAC by PCR genotyping. Nine of these 11 pups produced
a PCR product for all primer sets (Figure S1b), indicating
integration of an intact BAC construct. Two of eleven lines
integrated a partial construct (Table 2).
Assessment of transgene copy number by qPCR in the founders
indicated HB4 and HB6 as the two lines with the highest copy
number (Figure S1c & d). These were selected for further study,
and found to have comparable levels of HIP14 expression (data
not shown). Line HB4 was crossed to the existing Hip142/2 line
in order to asses for rescue in the present study.
mRNA levels in WT, Hip142/2, and BAC mice
Intron-spanning primers specific for human HIP14 transcript
confirmed the presence of human HIP14 expression in mice
carrying the BAC transgene (BAC). An absence of amplification in
the WT or Hip142/2 mice (Figure 1a) confirmed that this
transcript arises from the human HIP14 transgene.
As mRNA expression had not been previously assessed in
Hip142/2 mice, we investigated transcript levels in WT,
Figure 3. BAC-derived HIP14 rescues the neurochemical phenotype seen in Hip142/2 mice. Immunohistochemistry was assessed in mice
aged 1 month. Staining intensity was reduced in the Hip142/2 and restored to normal levels for a. DARRP-32 (WT: 98.861.4, Hip142/2: 71.664.9,
BAC: 92.463.9; ANOVA p,0.0001) and b. Enkephalin (WT: 91.968.5, Hip142/2: 40.568.2, BAC: 87.7612.3; ANOVA p=0.0002). c. Substance-P was
unchanged in all three genotypes (WT: 100.0614.8, Hip142/2: 110.8613.0, BAC: 106.466.4; ANOVA p=0.8)***p,0.0001, **p,0.01.
doi:10.1371/journal.pone.0036315.g003
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BAC-derived human HIP14. a. Repeated measures ANOVA in combined genders reveals a significant effect of genotype F(2,300)=600, p=0.0035.
Bonferroni post-hoc analysis reveals that BAC mice perform consistently better on the accelerating rotarod task than Hip142/2 mice (p,0.05 in trials
1,4; p,0.01 in trials 5,6) and superior to WT mice in later trials (p,0.05 trial 5). All other post-hoc comparisons are non-significant (p.0.05). n=25, 20,
and 17 for WT, Hip142/2, and BAC respectively. (b–j) Human HIP14 normalizes the hyperactivity observed in Hip142/2 mice to WT levels.
Spontaneous activity was assessed in Med Associates boxes at 3 and 6 months of age. Repeated measures ANOVA reveals a significant effect of
genotype in ambulatory time (b; F(2,53)=5.05, p=0.0099) and counts (e; F(2,53)=5.36, p=0.0076), stereotypic time (c; F(2,53)=19.70, p,0.0001)
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spanning primer was designed to anneal downstream (exon 14–15)
of the gene trap used to create the Hip142/2 mice, which lies in
intron 5. Murine Hip14 transcripts were significantly reduced in
Hip142/2 compared to WT littermates, but still detectable in
Hip142/2 cortex. This was not significantly affected by the
presence of the human HIP14 BAC in BAC mice (Figure 1b).
The human HIP14 transgene generates a modest level of
human HIP14 protein expression
We confirmed protein expression of HIP14 from the transgene
using a previously described HIP14 antibody [18], which detects
both mouse and human HIP14; thus, the band detected represents
total HIP14 protein. A faint band visible in Hip142/2 lanes was
confirmed to be non-specific, as it is not eliminated upon peptide
competition assay using a .500 molar excess of the peptide used
to generate the antibody (Figure S2). The human HIP14 transgene
is expressed at 36% and 35% of WT levels in striatum (Figure 1c)
and cortex (Figure 1d) respectively. Protein expression was
normalized to a beta tubulin loading control, and values are
shown relative to wildtype levels. HIP14 levels were significantly
increased in BAC mice relative to Hip142/2 in both striatum
(p=0.0091 normalized to WT, p=0.0083 as raw values) and in
cortex (p=0.0016 normalized to WT, p=0.019 as raw values).
Human HIP14 compensates for the neuropathological
deficits in Hip142/2 mice
Mice lacking murine Hip14 demonstrate neuropathological
deficits, including a 17% loss in striatal volume by embryonic day
E17.5, and an accompanying reduction in striatal neuron count
[23]. In order to assess whether the protein expressed from the
human HIP14 BAC is functional, we assessed a series of similar
neuropathological endpoints in Hip142/2 mice carrying the
human HIP14 BAC transgene, as compared to wildtype and
Hip142/2 littermates.
Brain weight is significantly decreased in Hip142/2 mice
throughout their lifespan [23]. In the current study, whole brain
weight and cerebellum are significantly decreased at 1 month in
Hip142/2 mice relative to WT; BAC mice are not significantly
different from WT in whole brain, cerebellum, or forebrain weight
(Figures 2a–c). One-way ANOVA analysis shows significant rescue
in cerebellum (Figure 2b) and a trend to restoration of WT values
in whole brain (Figure 2a) and forebrain (Figure 2c). Similar
observations are seen at 3 months (data not shown).
Similar to previous findings [23], Hip142/2 mice demonstrate
a 15.7% reduction in striatal volume at 1 month. This is fully
rescued to wildtype levels in Hip142/2 carrying the BAC
transgene (Figure 2d). Striatal neuron count is reduced by 14.3%
at 1 month in Hip142/2 mice and this is also significantly rescued
to WT values in BAC (Figure 2e). Finally, an 11.9% reduction of
cortical volume in Hip142/2 at 1 month is rescued in the
presence of human HIP14 (Figure 2f).
and counts (f; F(2,53)=15.13, p,0.0001), distance traveled (d; F(2,53)=3.60, p=0.034), time resting (g;(2,53)=4.99, p=0.010), and ambulatory
episodes (j; F(2,53)=8.68, p=0.0005). A significant effect was not seen in vertical counts (h; F(2,51)=1.89, p=0.1611), and average velocity (i;
F(2,54)=0.68, p=0.51). The most robust effects were observed for stereotypic time (c) and counts (f). Single-housed mice were excluded from all
analyses.*p,0.05, **p,0.01, ***p,0.0001.
doi:10.1371/journal.pone.0036315.g004
Figure 5. Rescue of palmitoylation of key HIP14 in substrates in the Hip142/2 mouse. Rescue of palmitoylation deficits of key HIP14
substrates in the Hip142/2 mouse, as assessed by Biotin BMCC assay on HIP14 substrates PSD-95 (a) and SNAP-25 (b). ANOVA p=20.007, n=5 each.
*p,0.05.
doi:10.1371/journal.pone.0036315.g005
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in Hip142/2 MSNs
The striatal neuron populations affected in HD consist of
GABAergic projection neurons and parvalbuminergic interneur-
ons, while other neuron populations in the striatum remain
relatively spared. The majority (95%) of striatal neurons consist of
projection neurons; therefore, the striatal atrophy and cell loss
observed in HD is largely due to loss of striatal GABAergic MSNs,
cells that express high levels of DARPP-32 [37]. These MSNs are
subdivided into two types: those expressing enkephalin and
dopamine D2 receptors, and those expressing substance-P and
dopamine D1 receptors. Levels of enkephalin and DARPP-32 are
affected early in HD, whereas substance P remains largely
unchanged until later in the disease [37]. As in HD patients,
Hip142/2 mice demonstrate reduced levels of DARPP-32 and
enkephalin in the striatum, while levels of substance-P are
unchanged [23]. Similar to previous findings, striatal levels of
DARPP-32 were reduced by ,28% in Hip142/2 mice as
compared to wildtype, and this was restored to wildtype levels in
Hip142/2 expressing the human HIP14 BAC (Figure 3a).
Enkephalin levels were reduced by ,56% compared to wildtype,
while the BAC mice were similar to wildtype (Figure 3b). Striatal
levels of substance-P were similar for all genotypes (Figure 3c).
This data demonstrates that BAC-derived human HIP14 com-
pensates for the neurochemical deficits observed in the Hip142/2
mice.
Motor coordination impairments & altered locomotor
activity in the Hip142/2 mouse is restored to normal by
human HIP14
Hip142/2 mice demonstrate deficits in motor coordination as
early as 3 months of age [23]. We therefore assessed mice for
performance on an accelerating rotarod at 3 and 6 months of age.
Repeated measures ANOVA reveals a significant effect of
genotype (Figure 4a). BAC mice performed consistently better
than Hip142/2 littermates, remaining on the rotarod apparatus
for a longer time before falling. BAC performance was also
superior to WT littermates, and this was more apparent at later
trials. A non-significant trend of WT performance superior to
Hip142/2 is apparent. The consistently superior performance in
BAC mice suggests that human HIP14 BAC can completely
compensate for motor coordination deficits seen in Hip142/2
mice.
Hip142/2 mice are hyperactive in various measures of dark-
phase assessment of spontaneous activity, similar to the observa-
tions of hyperactivity in young YAC128 mice [24,25]. Spontanous
activity measures were assessed at 3 and 6 months of age
(Figure 4b–j). The most robust changes were observed in
stereotypic time (Figure 4c) and counts (Figure 4f), where repeated
measures ANOVA revealed a significant effect of genotype. Post-
hoc Bonferroni testing revealed an increase in both measures in
Hip142/2 vs. WT, and a robust rescue in BAC mice. A
significant effect of genotype was also observed in ambulatory time
(Figure 4b) and counts (Figure 4e), distance traveled (Figure 4d),
time resting (Figure 4g), and ambulatory episodes (Figure 4j),
where Hip142/2 mice displayed hyperactivity and a normaliza-
tion to wildtype values in BAC was observed. In summary, human
HIP14 compensates for the behavioral deficits observed in mice
lacking murine Hip14.
Palmitoylation deficits of HIP14 substrates in Hip142/2
mice are normalized to wildtype levels by human HIP14
HIP14 functions as a PAT for a number of critical neuronal
proteins, including PSD-95 and SNAP-25 among others [19].
Palmitoylation of these neuronal proteins is decreased in the
Hip142/2 mouse model, and the defect in palmitoylation may
underlie defects in trafficking observed in HD [23]. We sought to
Figure 6. BAC-derived Human HIP14 is not sufficient to rescue body weight in the Hip142/2 mice. Hip142/2 mice demonstrate reduced
body weight as early as 2 weeks of age (data not shown). a. Body weight is decreased in Hip142/2 females (89.2% of WT) at 3 months of age, and
this is partially rescued (93.8% of WT) in BAC mice (WT 23.4760.76, Hip142/2 20.9460.23 g, BAC 22.0260.44 g). At 6 months, a similar partial rescue
is observed (WT 30.0061.74, Hip142/2 24.7560.49 g and 82.5% of WT, BAC 26.2960.69 g and 87.6% of WT). Repeated measures ANOVA reveals
a significant effect of genotype in females alone (F(2,27)=7.53, p=0.0025). Bonferroni post-tests reveal that WT differs significantly from both
Hip142/2 (p,0.0001) and BAC (p,0.01). n=10, 10, and 9 for WT, Hip142/2, and BAC respectively. b. In males, Hip142/2 body weight is similarly
decreased at 3 months (86.7% of WT) with partial rescue (91.7% of WT) in BAC (WT 28.7960.56, Hip142/2 24.9560.57 g, BAC 26.3960.47 g). By 6
months, partial rescue is further apparent (WT 33.9160.71, Hip142/2 28.3060.70 g and 83.45% of WT, BAC 30.7860.44 g and 90.75% of WT). A
highly significant effect of genotype is present in males (F(2,37)=26.81, p,0.0001). Bonferroni post-tests reveal a highly significant difference
between WT and Hip142/2 at 3 and 6 months of age (p,0.0001), and a significant, but less robust, difference between WT and BAC mice at both
ages (3 months p,0.05, 6 months p,0.01). However, BAC mice are also significantly different from Hip142/2 at both 3 (p,0.05) and 6 months
(p,0.0001). n=15, 10, and 8 for WT, Hip142/2, and BAC respectively.
doi:10.1371/journal.pone.0036315.g006
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human HIP14 is intact, and to assess whether the human protein
product can compensate for the loss of murine HIP14. Similar to
previous findings, we observed reduced palmitoylation of PSD-95
in the Hip142/2 mice (Figure 5a). Palmitoylation of SNAP-25
was similarly reduced in the Hip142/2 mice, and returned to
wildtype levels in the BAC mouse (Figure 5b).
The reduction in body weight seen in Hip142/2 mice is
only partially rescued by human HIP14
One of the features of HD in human patients is a progressive
loss of weight [15], and Hip142/2 mice fail to gain weight [23].
We therefore assessed whether BAC-derived human HIP14 can
compensate for this deficit. Hip142/2 mice aged 3 months
demonstrate reduced body weight relative to WT, and this is
partially rescued by human HIP14 in BAC mice in both genders
(Figure 6). This pattern is more apparent by 6 months of age in
both females (Hip142/2 82.5% and BAC 87.6% of WT) and
males (Hip142/2 83.5% and BAC 90.8% of WT). Weekly
measurements in a small subset of mice revealed that a similar
pattern of partial rescue in body weight is present at early as 2
weeks of age (data not shown).
Discussion
In this study we have demonstrated that human HIP14 can
compensate for the Hip142/2 phenotype in functional measures
of neuropathology, behavior, and PAT enzyme function. The
similarities in phenotype between HD and the Hip142/2 mice
highlighted a potentially important role for HIP14 in the
pathogenesis of HD. However, it remained to be conclusively
demonstrated that these phenotypes are the result of loss of HIP14
itself, and not, for example, a spontaneous mutation or a by-
product of unintended mutagenesis events occurring in the
generation of the Hip142/2 mouse model [38]. We created
humanized HIP14 BAC transgenic mice by crossing human
HIP14 BAC mice to mice lacking murine Hip14.
qRT-PCR experiments demonstrate that the transgene is
expressed in BAC mice, but entirely absent in WT and
Hip142/2 mice. However, the murine Hip14 transcript is
detectable in the Hip142/2 and BAC mice. This is not without
precedent; similar detection of mRNA transcripts in gene-trapped
mouse models has been previously reported [39–43]. It is possible
that alternative splicing may allow excision of the gene trap vector,
resulting in a low level of expression of the WT transcript.
However, whether murine HIP14 is generated from the deleted
transcript in the Hip142/2 mice was unclear. To determine if
HIP14 protein is completely absent in the Hip142/2 mice, and to
determine the level of HIP14 overexpression from the human
BAC, we performed western immunoblotting.
Western blot analysis in cortex and striatum demonstrates loss
of HIP14 in Hip142/2 mice, and expression at ,35% of
wildtype levels in BAC mice. Therefore, we have confirmed that
human HIP14 is expressed from the BAC transgene. A faint band
appeared in the Hip142/2 mice. This band appears to be non-
specific, as it remains after the antibody was inactivated with
a peptide competition assay (Figure S2), suggesting that any Hip14
mRNA generated does not generate HIP14 protein.
As human and mouse HIP14 protein are highly similar (98% of
amino acids identical), we anticipated that the human transgene
would compensate for the loss of its murine ortholog. Previous
studies demonstrated rescue of the murine huntingtin (Hdh2/2)
knockout phenotype by human HTT despite only 90% conserved
amino acid identity [29,44]. In addition, previous findings showed
that human HIP14 is able to partially compensate for the
endocytosis defect and temperature sensitive lethality resulting
from loss of Akr1p, a yeast ortholog of HIP14 [18]. As anticipated,
BAC-derived human HIP14 was capable of restoring a normal
phenotype in neuropathological, behavioral, and functional
enzymatic measures in mice lacking murine Hip14. Thus, our
findings suggest that human HIP14 undergoes the necessary post-
translational modifications and protein interactions necessary to
perform these functions in the mouse cellular context, and can
compensate for the loss of its murine ortholog in most measures
assessed. Because neuropathological deficits in the Hip142/2
mouse appear during prenatal development by embryonic day
E17.5, these findings furthermore suggest that the human HIP14
BAC transgene is appropriately expressed in prenatal develop-
ment.
As part of our study, we sought to assess what levels of HIP14
expression are sufficient to rescue the Hip142/2 phenotype.
Surprisingly, the human HIP14 transgene is expressed at only
,35% of endogenous levels in cortex and striatum of mice lacking
murine Hip14. Despite this relatively low level of expression, the
neuropathological, behavioral, and biochemical measures of
HIP14 assessed in this study are all fully rescued.
It is interesting to note previous investigations of another
DHHC PAT null mouse model, Zdhhc82/2, which revealed
similar deficits in both heterozygotes (Zdhhc8+/2) and homo-
zygotes (Zdhhc82/2) relative to WT littermates [11]. For
example, the density of glutamatergic synaptic contacts was
decreased to a similar extent in both Zdhhc8+/2 and Zdhhc82/2
mice. In addition, the number of mushroom spines, number of
dendritic branch points, and number of primary dendrites were
also affected in both genotypes [11]. In contrast, neuropatholog-
ical assessments of Hip14+/2 mice at 12 months revealed no loss
in striatal volume, an endpoint showing the greatest changes in
Hip142/2 mice as early as E17.5 [23]. As Hip14+/2 mice
express only 50% of endogenous HIP14, this data is in agreement
with the findings of the current study; namely, that only a fraction
of endogenous HIP14 expression levels are sufficient to prevent the
neuropathological changes observed in Hip142/2 mice.
Many studies report partial rescue of murine knockout
phenotypes by the human ortholog transgene. For example,
human NR2E1 rescues a murine Nr2e1 null phenotype in all
aspects except for retinal vessel number, which appeared to be
partially rescued but still significantly different from wildtype mice
[33]. Another study demonstrated the ability of a human CFTR
YAC transgene to partially rescue the murine knockout phenotype
[45].
While most major endpoints in the Hip142/2 mice were
restored to wildtype levels in the presence of the human HIP14
transgene, the reduced body weight observed in the Hip142/2
mice was only partially restored to wildtype levels. The incomplete
rescue of body weight in the humanized mice may occur for
a number of reasons. Firstly, as observed for retinal vessel number
in a similar study on Nr2e1 null mice [33], maintenance of some
physiological features may be more sensitive to gene dosage than
the other endpoints assessed in this study. A higher level of
expression (.35% of endogenous) may be required to restore body
weight to wildtype levels. Alternatively, the role of HIP14 in the
periphery may require a regulatory cis-element that is absent in
the human BAC transgene used in this study. Finally, some
functions of HIP14 may require an interaction between transcrip-
tional machinery and DNA regulatory elements that is in-
compatible between the former in mice and the latter in humans.
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In summary, we have generated the first transgenic mouse
model for HIP14, and demonstrate intact palmitoyl-transferease
activity in a transgenic DHHC PAT model. Humanized mice for
HIP14 were able to rescue defects in neuropathology, behavior,
and HIP14 PAT activity, and partially restored body weight to
wildtype levels. We report that human HIP14 compensates for the
key features resulting from loss of the murine ortholog at an
expression level equivalent to only ,1/3 that of endogenous
murine HIP14, which is sufficient for full rescue of most
phenotypes.
This latter finding carries important therapeutic implications.
We have previously shown that HIP14 is dysfunctional and
displays impaired PAT activity in the brain of the YAC128 mouse
model of HD despite normal levels of HIP14 protein [23]. The
current study suggests that therapeutic interventions in human HD
patients could be directed toward approaches to increase HIP14
activity, and that rescue of some phenotypes in YAC128 mice may
be achieved with less than wildtype levels of functional HIP14.
Supporting Information
Figure S1 Creation of a HIP14 BAC transgenic mouse. a.
Schematic of genomic DNA included in human HIP14 BAC
RP11-463M12, which includes ,84 kb of upstream and ,6k b
downstream regulatory sequence, excluding other intact genes or
clearly defined promoter sequences. Numbers indicate location of
seven primer pairs used to ascertain founders, listed in Table 1. b.
PCR genotyping confirmation of tail DNA from FVB mice
generated from microinjections with a human HIP14 BAC. Eleven
mice tested positive for the transgene, of which 9 were positive for
all 7 primer sets assessed. Figure shows results for primer pair 2
(Table 1). BAC=HIP14 BAC (5 ng), S=FVB WT genomic DNA
spiked with HIP14 BAC at 1-copy number (200 ng), WT=FVB
WT genomic DNA, H20=ddH2O, *=these mice not positive on
all primer sets. c. qPCR assessment of relative transgene genomic
copy number in HIP14 BAC founder mice. HIP14 BAC-spiked
FVB genomic DNA was run in a standard curve for estimation of
BAC copy number on the same plate as genomic tail DNA from
each HIP14 BAC founder mouse. Relative quantitation was
calculated relative to the standard curve one-copy equivalent.
Each sample was loaded in triplicate, and the plate run in
duplicate. Error bars indicate the variation between the two plates.
The highest BAC copy number was detected in lines HB2, HB4,
and HB6. HB5F1 and HB7F1 are tail DNA from F1 offspring of
founders HB5 and HB7, respectively, run on the same plate. d.
qPCR assessment transgene copy number in the HIP14 BAC F1
offspring reveals a pattern consistent with that observed in
founders (n=6). Copy number estimates of F1 were calculated
relative to HB7.
(TIF)
Figure S2 Peptide Competition Assay on PEP1 HD82
antibody for HIP14. Identical WT and Hip142/2 samples of
(a) Cortex and (b) Striatum lysate were run in duplicate on the
same gel on SDS-PAGE gels and transferred to PVDF membrane.
After blocking, membranes were cut in half and subsequently
processed in parallel. One half of each membrane was incubated
in PEP1 primary antibody according to the standard protocol
(control). The remaining half of the membrane was inciubated
with PEP1 primary antibody solution that had been pre-incubated
with a .500 molar excess of the peptide used to generate the
antibody. Subsequently, both membranes were washed and
incubated with secondary antibody according to the standard
protocol described in Materials and Methods. Beta tubulin was
probed as a loading control. Incubation with peptide-competed
primary antibody enables identification of non-specific bands. The
bands that disappear upon peptide-competition are specifically
recognized by the antibody; those that remain are non-specific.
Notably, the faint band apparent in Hip142/2 samples remains
in the peptide-competed membrane, indicating that this is a non-
specific band.
(TIF)
Acknowledgments
We thank Drs. Rona Graham and Mahmoud Pouladi for proofreading the
manuscript.
Author Contributions
Conceived and designed the experiments: FBY SF AS SSS RRS MRH.
Performed the experiments: FBY SF AS YD SSS NCMT KH RRS WZ
NB CK. Analyzed the data: FBY SF AS YD SSS NCMT KH MRH.
Contributed reagents/materials/analysis tools: FBY SF AS YD SSS RRS
MRH. Wrote the paper: FBY SF AS YD SSS NCMT KH RRS WZ NB
CK MRH. Approval of submitted version of article: FBY SF AS YD SSS
NCMT KH RRS WZ NB CK MRH.
References
1. Linder ME, Deschenes RJ (2007) Palmitoylation: policing protein stability and
traffic. Nat Rev Mol Cell Biol 8: 74–84.
2. Huang K, El-Husseini A (2005) Modulation of neuronal protein trafficking and
function by palmitoylation. Curr Opin Neurobiol 15: 527–535.
3. Greaves J, Chamberlain LH (2011) DHHC palmitoyl transferases: substrate
interactions and (patho)physiology. Trends Biochem Sci 36: 245–253.
4. Huang K, Sanders S, Singaraja R, Orban P, Cijsouw T, et al. (2009) Neuronal
palmitoyl acyl transferases exhibit distinct substrate specificity. FASEB J 23:
2605–2615.
5. El-Husseini AE-D, Bredt DS (2002) Protein palmitoylation: a regulator of
neuronal development and function. Nat Rev Neurosci 3: 791–802.
6. Fukata Y, Fukata M (2010) Protein palmitoylation in neuronal development and
synaptic plasticity. Nat Rev Neurosci 11: 161–175.
7. Mansouri MR, Marklund L, Gustavsson P, Davey E, Carlsson B, et al. (2005)
Loss of ZDHHC15 expression in a woman with a balanced translocation
t(X;15)(q13.3; en) and severe mental retardation. Eur J Hum Genet 13:
970–977.
8. Raymond FL, Tarpey PS, Edkins S, Tofts C, OMeara S, et al. (2007) Mutations
in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause
X-linked mental retardation associated with a Marfanoid habitus. Am J Hum
Genet 80: 982–987.
9. Chen W-Y, Shi Y-Y, Zheng Y-L, Zhao X-Z, Zhang G-J, et al. (2004) Case-
control study and transmission disequilibrium test provide consistent evidence
for association between schizophrenia and genetic variation in the 22q11 gene
ZDHHC8. Hum Mol Genet 13: 2991–2995.
10. Mukai J, Liu H, Burt RA, Swor DE, Lai W-S, et al. (2004) Evidence that the
gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat Genet 36:
725–731.
11. Mukai J, Dhilla A, Drew LJ, Stark KL, Cao L, et al. (2008) Palmitoylation-
dependent neurodevelopmental deficits in a mouse model of 22q11 microdele-
tion. Nat Neurosci 11: 1302–1310.
12. Sidera C, Parsons R, Austen B (2005) Post-translational processing of beta-
secretase in Alzheimer’s disease. Proteomics 5: 1533–1543.
13. Zeidman R, Jackson C, Magee A (2009) Protein acyl thioesterases (Review). Mol
Membr Biol 26: 32–41.
14. Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, et al. (1995) Mutations
in the palmitoyl protein thioesterase gene. Nature 376: 584–587.
15. Roos RA (2010) Huntington’s disease: a clinical review. Orphanet J Rare Dis 5:
40.
16. Vonsattel JPG, Difiglia M (1998) Huntington Disease. J Neuropath Exp Neur
57: 369–384.
17. Huntington Disease Collaborative Research Group (1993) A novel gene
containing a trinucleotide repeat that is expanded and unstable on Huntington’s
disease chromosomes.The Huntington’s Disease Collaborative Research Group.
Cell 72: 971–983.
Human HIP14 Rescues Loss of Murine HIP14 In Vivo
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e3631518. Singaraja RR, Hadano S, Metzler M, Givan S, Wellington CL, et al. (2002)
HIP14, a novel ankyrin domain-containing protein, links huntingtin to
intracellular trafficking and endocytosis Hum Mol Genet 11: 2815–2828.
19. Huang K, Yanai A, Kang R, Arstikaitis P, Singaraja R, et al. (2004) Huntingtin-
Interacting Protein HIP14 Is a palmitoyl transferase involved in palmitoylation
and trafficking of multiple neuronal proteins. Neuron 44: 977–986.
20. Harjes P, Wanker EE (2003) The hunt for huntingtin function: interaction
partners tell many different stories. Trends Biochem Sci 28: 425–433.
21. Huang K, Sanders SS, Kang R, Sutton L, Wan J, et al. (2011) Wildtype HTT
modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14.
Hum Mol Genet 20: 3356–3365.
22. Yanai A, Huang K, Kang R, Singaraja RR, Arstikaitis P, et al. (2006)
Palmitoylation of huntingtin by HIP14is essential for its trafficking and function.
Nat Neurosci 9: 824–831.
23. Singaraja RR, Huang K, Sanders SS, Milnerwood A, Hines R, et al. (2011)
Altered palmitoylation and neuropathological deficits in mice lacking HIP14.
Hum Mol Genet 20: 3899–3909.
24. Slow EJ, Van Raamsdonk JM, Rogers D, Coleman SH, Graham RK, et al.
(2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington
Disease. Hum Mol Genet 12: 1555–1567.
25. Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, et al. (2005)
Cognitive dysfunction precedes neuropathology and motor abnormalities in the
YAC128 mouse model of Huntington’s Disease. J Neurosci 25: 4169–4180.
26. Van Raamsdonk JM, Warby SC, Hayden MR (2007) Selective degeneration in
YAC mouse models of Huntington disease. Brain Res Bull 72: 124–131.
27. Gong S, Yang X (2005) Modification of bacterial artificial chromosomes (BACs)
and preparation of intact BAC DNA for generation of transgenic mice. Current
Protocols in Neuroscience: John Wiley & Sons, Inc.. pp 1–14.
28. Yang XW, Model P, Heintz N (1997) Homologous recombination based
modification in Esherichia coli and germline transmission in transgenic mice of
a bacterial artificial chromosome. Nat Biotechnol 15: 859–865.
29. Hodgson JG, Smith DJ, McCutcheon K, Koide HB, Nishiyama K, et al. (1996)
Human huntingtin derived from YAC transgenes compensates for loss of murine
huntingtin by rescue of the embryonic lethal phenotype Hum Mol Genet 5:
1875–1885.
30. Sarsero JP, Li L, Holloway TP, Voullaire L, Gazeas S, et al. (2004) Human
BAC-mediated rescue of the Friedreich ataxia knockout mutation in transgenic
mice. Mamm Genome 15: 370–382.
31. Coutinho JM, Singaraja RR, Kang M, Arenillas DJ, Bertram LN, et al. (2005)
Complete functional rescue of the ABCA1 mouse by human BAC transgenesis.
J Lipid Res 46: 1113–1123.
32. Bradley SV, Hyun TS, Oravecz-Wilson KI, Li L, Waldorff EI, et al. (2007)
Degenerative phenotypes caused by the combined deficiency of murine HIP1
and HIP1r are rescued by human HIP1. Hum Mol Genet 16: 1279–1292.
33. Abrahams BS, Kwok MCH, Trinh E, Budaghzadeh S, Hossain SM, et al. (2005)
Pathological aggression in ‘‘Fierce’’ mice corrected by human Nuclear Receptor
2E1. J Neurosci 25: 6263–6270.
34. Chen JY, Levy-Wilson B, Goodart S, Cooper AD (2002) Mice expressing the
human CYP7A1 gene in the mouse CYP7A1 knock-out background lack
induction of CYP7A1 expression by cholesterol feeding and have increased
hypercholesterolemia when fed a high fat diet. J Biol Chem 277: 42588–42595.
35. Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, et al. (2004)
Diminished hepatocellular proliferation in mice humanized for the nuclear
receptor Peroxisome Proliferator-Activated Receptor alpha Cancer Res 64:
3849–3854.
36. Drisdel RC, Green W (2004) Labeling and quantifying sites of protein
palmitoylation. Biotechniques 36: 276–285.
37. Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, et al. (2004)
Differential loss of striatal projection systems in Huntington’s disease:
a quantitative immunohistochemical study. J Chem Neuroanat 27: 143–164.
38. Osokine I, Hsu R, Loeb GB, McManus MT (2008) Unintentional miRNA
ablation is a risk factor in gene knockout studies: A short report. PLoS Genet 4:
e34.
39. Hoshii T, Takeo T, Nakagata N, Takeya M, Araki K, et al. (2007) LGR4
regulates the postnatal development and integrity of male reproductive tracts in
mice. Biology of Reproduction 76: 303–313.
40. Lako M, Hole N (2000) Searching the unknown with gene trapping. Expert
Reviews in Molecular Medicine 2: 1–11.
41. Roshon M, DeGregori JV, Ruley HE (2003) Gene trap mutagenesis of hnRNP
A2/B1: a cryptic 39 splice site in the neomycin resistance gene allows continued
expression of the disrupted cellular gene. BMC Genomics 4: 1–11.
42. Trimborn M, Ghani M, Walther DJ, Dopatka M, Dutrannoy V, et al. (2010)
Establishment of a mouse model with misregulated chromosome condensation
due to defective Mcph1 function. PLoS One 5: 1–13.
43. Voss AK, Thomas T, Gruss P (1998) Efficiency assessment of the gene trap
approach. Developmental Dynamics 212: 171–180.
44. Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, et al. (2001)
Wildtype huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.
Am J Hum Genet 68: 313–324.
45. Manson AL, Trezise AEO, MacVinish LJ, Kasschau KD, Birchall N, et al.
(1997) Complementation of null CF mice with a human CFTR YAC transgene.
EMBO J 16: 4238–4249.
Human HIP14 Rescues Loss of Murine HIP14 In Vivo
PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36315